Market Insight - How the IMI is reinvigorating European pharma research
This article was originally published in Scrip
The Innovative Medicines Initiative (IMI) is a public-private partnership which aims to bolster Europe's competitive edge in pharmaceutical research and improve the mechanisms for bringing new medicines to the marketplace. Dr David Pountney, Colin Maher and Nick Beckett review the achievements to date and discuss with GlaxoSmithKline's Dr Jackie Hunter what the future may hold.
You may also be interested in...
The Trump administration does not believe its partnership with industry on therapeutics for COVID-19 should include conditions on pricing, US Health Secretary Alex Azar tells Congress.